Plus, how I'm playing Monday's E-Mini S&P 500 futures.

3 Biotechs to Buy This Summer Real Money Pro($)

These companies will do well, despite a range bound sector.
The bulls have not been able to build on strong action -- and the bears have been even more inept.
There still will be winners and losers, but the new administration's FDA is a net plus for the industry.
But I'm managing positions carefully and don't trust the upside momentum very much.
The two giants likely won't be home runs, but they remain stalwarts in the biotech space.
The two giants likely won't be home runs, but they remain stalwarts in the biotech space.
Dynavax Technologies, Ocular Therapeutix and Neos Therapeutics have big drug approval dates ahead.
The trade is the out-of-the-money, bullishly biased vertical call spread expiring in August.
This is a typical rotation based on changes in the market due to money chasing performance.

Columnist Conversations

Foot Locker's (FL) less than expected quarterly earnings set off a round of selling the entire athletic appare...
View Chart »  View in New Window » Gold has met the first upside target off the last setup zon...
View Chart »  View in New Window »
View Chart »  View in New Window »


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.